Seres Therapeutics Inc (MCRB) Given Average Rating of “Buy” by Analysts

Shares of Seres Therapeutics Inc (NASDAQ:MCRB) have been assigned an average recommendation of “Buy” from the twelve ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $19.14.

Several brokerages recently commented on MCRB. BidaskClub downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. Zacks Investment Research downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. CIBC began coverage on shares of Seres Therapeutics in a research report on Friday, October 13th. They set an “outperform” rating and a $19.00 price objective on the stock. Oppenheimer began coverage on shares of Seres Therapeutics in a research report on Thursday, October 12th. They set an “outperform” rating and a $19.00 price objective on the stock. Finally, Citigroup began coverage on shares of Seres Therapeutics in a research report on Thursday, October 12th. They set a “positive” rating and a $19.00 price objective on the stock.

Shares of Seres Therapeutics (MCRB) opened at $8.58 on Friday. The firm has a market cap of $352.61, a PE ratio of -4.05 and a beta of 0.24. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.53 and a quick ratio of 6.53. Seres Therapeutics has a 1 year low of $8.54 and a 1 year high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.17) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.22. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. The company had revenue of $23.00 million for the quarter, compared to the consensus estimate of $17.29 million. During the same period in the prior year, the firm posted ($0.46) EPS. Seres Therapeutics’s revenue for the quarter was up 76.9% on a year-over-year basis. research analysts anticipate that Seres Therapeutics will post -2.33 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC purchased a new stake in shares of Seres Therapeutics during the 3rd quarter valued at about $2,165,000. Northern Trust Corp boosted its holdings in shares of Seres Therapeutics by 16.2% during the 2nd quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock valued at $2,664,000 after acquiring an additional 32,875 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Seres Therapeutics by 39.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock valued at $6,160,000 after acquiring an additional 106,479 shares during the last quarter. State Street Corp boosted its holdings in shares of Seres Therapeutics by 12.0% during the 2nd quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock valued at $3,637,000 after acquiring an additional 34,393 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Seres Therapeutics by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock valued at $17,911,000 after acquiring an additional 19,363 shares during the last quarter. 76.48% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Seres Therapeutics Inc (MCRB) Given Average Rating of “Buy” by Analysts” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/09/seres-therapeutics-inc-mcrb-given-average-rating-of-buy-by-analysts.html.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply